Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Why Should You Retain Molina Healthcare In Your Portfolio?

Published 12/30/2019, 12:05 AM
Updated 07/09/2023, 06:31 AM

Molina Healthcare, Inc (NYSE:MOH) has been in investor’s good books, riding high on its solid outlook and restructuring plus profitability improvement plan.

Its VGM Score of A is also impressive. Here V stands for Value, G for Growth and M for Momentum with the score being a weighted combination of all three factors.

Now let’s see what makes this stock an investor favorite.

The company has seen consistent growth in its revenue base over the past several years. Although the metric dropped in the first nine months of 2019, the company’s solid fundamentals, such as premium revenues would likely help the same grow going forward. Given the restructuring initiatives and developmental strategies, we expect the top line to continue rising moving ahead. The company estimates 10-12% revenue growth over the long term.

Molina has been gaining from its 2017 restructuring and profitability improvement plan. The plan included streamlining of organizational structure to improve efficiency as well as the speed and quality of decision-making. This initiative led to a total expense decline of 13.2% and 12.3% in 2018 and the first nine months of 2019, respectively. We expect this initiative to help curb costs further.

In fact, the company even divested its units, Pathways Health and Community Support, LLC and Molina Medicaid Solutions, which might help it focus on core growth areas.

We are also hopeful as there is an attractive pipeline of Medicaid opportunities. The company recently announced that its Kentucky health plan subsidiary was awarded a new five-year Kentucky Medicaid managed care contract, which would likely aid its growth in Medicaid business. We expect this momentum to continue in the future on the back of contract wins.

Following third-quarter results, the company hiked its 2019 outlook. It now expects its earnings in the range of $11.3-$11.5, tightened from the earlier guidance of $11.2-$11.5 per share. This should instill investor’s confidence in the stock.

However, its membership has been decreasing since 2018, which persistently bothers. The company expects its 2019 Marketplace end-of-year enrollment to decline to around 270,000 members due to attrition. Moreover, the company’s Medicaid membership suffered due to loss of contracts in Florida, New Mexico and Texas, which remains a concern.

In a year’s time, shares of this Zacks Rank #3 (Hold) have rallied 17%, underperforming its industry’s growth of 19.2%. Its earnings managed to surpass the Zacks Consensus Estimate in the trailing four quarters, the average being 51.6%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Stocks to Consider

Investors interested in the medical sector might consider some better-ranked stocks like Select Medical Holdings Corporation (NYSE:SEM) , WellCare Health Plans, Inc. (NYSE:WCG) and Genesis Healthcare, Inc. (NYSE:GEN) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Select Medical Holdings operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics and occupational health centers. In the trailing four quarters, the company’s average beat was 11.07%. The stock sports a Zacks Rank #1.

WellCare Health offers managed care services to government-sponsored health care programs. The company pulled off average positive surprise of 17.32% in the preceding four quarters. It carries a Zacks Rank #2 (Buy).

Genesis Healthcare operates skilled nursing facilities and assisted/senior living homes. In the last four quarters, the company delivered average beat of 80.96%. It has a Zacks Rank of 1.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



WellCare Health Plans, Inc. (WCG): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Molina Healthcare, Inc (MOH): Free Stock Analysis Report

Select Medical Holdings Corporation (SEM): Free Stock Analysis Report

Genesis Healthcare, Inc. (GEN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.